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1137-66 OTC Interval Prolongation Predicts Mortality in Heart 
Transplant Recipients 
Boian Vrtovec, Cyntlva D. Thomas, Rajko Radovancevic, Aria P. Yazdanbakhsh, 0. H. 
Frazier, Branislav Radovancevic, Texas Heart Institute, Houston, TX 
Background: Aithough OTC interval prolongation is considered a risk factor for adverse 
outcome in non-transplant populations, its predictive value in hear? transplant recipients 
has not been studied yet. 
Methods: QTc intervals were measured in 587 adult patients who underwent heart 
transplantation between May 1982 and January 2002. QT interval duration was deter- 
mined by averaging 3 consecutive beats in all 12 leads of the standard EGG and cor- 
rected with the Bazett formula. Baseline ECGs were obtained within 7 days after 
transplantation, and the follow-up ECGs were recorded annually at the time of routine 
angiography. Data on donor and recipient characteristics, post-transplant clinical course, 
and immunosuppression were collected; biopsies ware assessed for the presence of 
rejection; and angiograms were reviewed for the presence of transplant vasculopathy. 
Patients were followed over 7 f 5 years (range: 3 months - 17 years). 
Results: During follow-up, 241 patients died. The mean post-transplant QTc interval 
duration in these patients was comparable to the mean OTC interval in the remaining 
cohort (432 + 26 ms vs. 423 f 26 ms, p=O.O7). However, patients with a relative increase 
in QTc duration of more than 10% between first and second post-transplant year (dQTc 
>lO%) had a 6.7 times higher risk of dying when compared with patients with dQTc 
<IO% (p=O.O005). Although the incidence of transplant vasculopathy was higher in the 
patients who died (51% vs. 33% in the remaining cohort, p=O.Ol), dQTc ~10% was the 
only independent predictor of mortality on multivariate analysis (p=O.O008). 
Conclusions: A relative increase in QTc interval duration of more than 10% between the 
first and second post-transplant year is a strong, independent predictor of mortality in 
heart transplant recipients. 
1137-69 A Novel Long-Pentraxin PTXS, C-Reactive Protein, NT- 
Pro-BNP and Troponin-T During the First Six Months 
After Heart Transplant 
Roberto Latlni, Pasauale Fratto, Maria Frigerio, Fabrizio Oliva, Giuseppe Peri, Albert0 
Mantovani, Fabio Pasqualini, Stefano Signorini, Tarcisio Vago, Aldo P. Maggioni, Ettore 
Vitali, lstituto di Ricerche Farmacologiche. Milano. Italy, Ospedale Niguarda, Milano, Italy 
Background. PTX3 is a novel protein highly expressed by stimulated endothelium of 
coronary bed; it increases in plasma after MI. but it has not been studied in heart trans- 
plant (HTx). PTX3 might be involved in the complex immune response to HTx. Methods. 
PTX3 was assayed in 33 pts 52+18y(mean&D) in serial blood samples starting from 
41*33d after HTx, at the time of endomyocardlal biopsy (EMB). C-reactive protein 
(CRP), N-termmal-proBNP (Nt-proBNP) and troponin-T (Tn-T) were assayed in 13/33 pts 
with at least 3 samples, followed-up for 99+18d after HTx with 81 EMB [I to 8/pt]. Histo- 
logic rejection on EMP was graded by ISHLT. Results 23 episodes of class l/A and l/B 
rejection were diagnosed with 7 episodes of l/B treated with iv steroids. 
Medmn plasma concentrations at tune of EMB 
EMB PTX3 (“g/ml) CRP(mcg/ml) Nt-proBNP(pg/ml) Tn-T(ng/ml) 
33 pts 13pts 13pts 13pts 
Nag 1.57 2.36 1350 co.01 
l/A 1.43 0.93 1033 <O.Ol 
l/B 2.87 3.1 3780 0.053 
upper normal 2.06 2.87 88 to 334 0.04 
In a case of severe rejection leading to death, plasma PTX3 reached 3220 nglml. CRP, 
Nt-proBNP and Tn-T showed similar trends to PTX3 in relation to rejection. CRP was 84 
nglml in a pt with Pseudomonas infection and EMB nag, while PTX3 was normal. Tn-T 
and Nt-proBNP tended to be higher the closer to HTx was the first blood sample and 
when HTx was done in emergency. Nt-pro BNP was supranormal in 95% of the cases. I” 
absence of LV dysfunction (LVEF 6159%). Conclusions. PTX3 and the other markers 
are higher in l/B rejection. Early elevations of Tn-T might originate from cardiac ischemic 
Insult during HTx, while high initial Nt-pro BNP might reflect marked up-regulation of 
natriuretic peptides during end-stage heart failure leading to HTx. 
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633-l Quartile Analysis of the Baseline Aortic Preejection 
Interval as a Predictor of Response to Cardiac 
Resynchronization Therapy 
Martin G. St. John Sutton Ted J. Plappert, Kathryn E. Hilpisch, Edward C. Chinchoy, 
University of Pennsylvania, Philadelphia, PA, Medtronic, Inc., Minneapolis, MN 
The baseline aortic pre-ejection interval (bAPEI) is a Doppler index of time measured 
between ventricular depolarization and onset of ejection. It was hypothesized that large 
values of bAPEl would predict response to cardiac resynchronization therapy (CRT) in 
the MIRACLE trial. METHODS: Patients with an atrio-synchronous biventricular pacing 
device and atrio-venticular delay optimized for mitral filling ware randomized to CRT or 
control. Doppler echograms were recorded at baseline and 6 months for LV end-diastolic 
(EDV) and end-systolic (ESV) volume, and ejection fraction (EF), and analyzed by a core 
laboratory. NYHA class, B-minute hall walk, Quality of Life and peak Vq were mea- 
sured.RESULTS: Median quartile ranges of bAPEl were 5131, <I58 <I83 and >183ms 
(n=306). Patients were grouped according to upper and lower quartile of bAPEl values, 
and 6.month changes in clinical and echo parameters were compared. Significance was 
determined by the Wilcoxon rank sum test. Table (‘p<O.O5 between CRT and control; 
+p<O.O5 between bAPEI>l83ms CRT and bAPEl&l3lms CRT). CONCLUSIONS: 
CRT patients with bAPEl>183 ms had significantly greater improvements in LVEDV, 
LVESV, LVEF, 6-minute hall walk, and Quality of Life than CRT patients with bAPEl 
<131ms. CRT patients with bAPEl <13lms had no difference in changes in 6-minute hall 
walk, Quality of Life, peak V02, LVEDV, LVESV and LVEF than control patients with 
bAPEl <I31 ms. bAPEl may be useful for predicting the magnitude of response to CRT. 
Median values; baseline 
to 6mo 
NYHA 
6-minute hall walk 
distance 
Quality of Life 
Peak VO* 
LVEDV (cm3) 
LVESV (cm? 
LVEF (%) 
bAPEI</ 
=I 31 ms 
Control 
(n=46) 
-0.3+/-0.6 
-17+/-89 
-7+i/-22 -14+/-26 
-0.3+/-2.8 O.O+/-3.2 
-2+/-43 -7+/-44 
-5+l-44 -9+/-33 
1.6+/-7.7 2.0+/-7.4 
bAPEIc/ 
=13lms 
CRT (n=36) 
-0.7+/-0.7 * 
II+/-109 
bAPEl>183 bAPEl>l83 
ms Ins 
Control CRT (n=49) 
(n=28) 
-O. l +/-0.6 -l.O+/-0.7 ’ 
29+/-122 78+l-67 * + 
-1 O+/-23 -28+/-l 8 * + 
-0.2+/-3.2 1.4+/-3.0 
16+/-52 -62+/-71 * + 
6+/-49 -64+/-68 * + 
2.4+/-5.9 6.8+/-7.8 * 
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833-2 Resynchroniration Does Not Change the Incidence of 
Ventricular Arrhythmias 
Anael R. Leon James B. Young, William T. Abraham, for the MIRACLE ICD 
Investigators. The Carlyle Fraser Heari Center Emory University School of Medicine, 
Atlanta, GA 
Cardiac resynchronization (CRT) improves the quality of life and functional capacity in 
moderate to severe heart failure patients with a wide QRS and an indication for an 
implantable cardloverler defibrillator (ICD). We assessed the results from a large-scale 
randomwad trial to determine whether CRT changes the incidence of ventricular arrhyth- 
mias in this population. Methods The Multicenter InSync ICD Randomized Clinical Eval- 
uation (MIRACLE ICD) included heart failure patients !n NYHA functional class II/III/IV, 
QRS duration21 30 rns, left ventricular ejection fraction i 35% and a Class I indication for 
an ICD. Following successful implant of a system that combines biventricular pacing wth 
ICD functionality, patients were randomly assigned to biventricular pacing on (CRT) or 
bwentricular pacing off (Control) for 6 months. All patients had ICD treatment enabled. 
Comparisons of VTNF episodes par month between Control and CRT during the ran- 
domization period were made using a large-sample comparison of incidence test, while 
the p-value for comparing the probability of experiencing an episode of VTNF was calcu- 
lated using the log-rank test. Results. A total of 282 patients were randomized to Con- 
trol, and 272 patients to CRT. During the 6-month randomization period, 58 Control 
patients had 392 spontaneous VTNF episodes, while 53 CRT patients had 415 sponta- 
neous VTNF episodes. There is no difference behveen groups in the probability of a 
spontaneous VTNF episode occurring (~~0.75). Control patients averaged 0.30 epi- 
sodes par month, compared with 0.33 monthly episodes for CRT patients (p=O.20). Con- 
clusion. CRT appears neither to promote nor diminish the incidence of ventncular 
arrhythmias in patients with moderate to severe heart failure with a wide QRS and an 
indication for an ICD. 
